Abstract
The article gives data on epidemiology, pathogenesis, modern classification and the main clinical manifestations of Gaucher’s disease in children; it also gives criteria of differential diagnostics with other diseases. The article shows that the only effective method of treating Gaucher’s disease is pathogenic enzyme-substitutive therapy which arrests the main clinical manifestations of the disease improving life quality of patients without pronounced side effects. Imiglucerase is used for such treatment; it causes hydrolysis of glucocerebroside into glucose and ceramide (regular metabolism of membrane lipids). Imiglucerase is indicated for long-term enzyme-substitutive therapy in patients with confirmed Gaucher’s disease (types 1 and 3). It is recommended to monitor condition of patients in the setting of therapy in compliance with the requirements of the International Collaborative Gaucher Group. The article cites the main mistakes of diagnostics and management of such patients and ungrounded prescriptions when treating this disease.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.